Hot Investor Mandate: Early-Stage Life Science Development Group Invests in Therapeutics, Devices, Diagnostics, Open to All Technologies & Capable of Leading Rounds of Up to $20M

29 Oct

An early-stage life science development group currently backs more than 12 companies and the firm’s total investment across all technologies exceeds $100 million. The firm has a dual development strategy. The firm partners with academic inventors to found, manage, and develop companies to a point of exit or strategic partnering. When founding companies, the firm leverages non-dilutive grant funding where available alongside their investment group. The firm can also support early clinical-stage companies looking for financial and management support to perform clinical proof of concept studies; specifically a combination of investor funding and management support to round out the capabilities of the existing team. The firm and its affiliated investor groups have the ability to lead investment rounds of up to $20 million while also providing any required management support through its experienced team, including in preclinical, clinical and business development.

The firm invests across the biosciences space including Therapeutics, Diagnostics, and Medical Devices although the primary focus is on Therapeutics. The group is opportunistic in terms of subsectors and indications. Historically, the group has been active with companies developing novel therapeutics including drugs for defending against inhaled pathogenic threats, treatment of asthma, cancer, autoimmune diseases, and hearing loss, a biomedical assay platform technology, molecular diagnostics, antioxidant nanoparticles, robotic and imaging technologies, and cardiovascular devices.

The firm is interested in connecting with companies looking to generate clinical proof-of-concept data and that require funding as well as management support to complement the existing team. We are especially interested in companies that may have an interest in relocating to Houston.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: